Why Is MODERNA INC (MRNA) Stock Up Today?

Moderna Inc (MRNA) surged 15.73% to $160.75 in a single session, driven by positive developments in its collaboration with Merck on a personalized mRNA cancer vaccine. The stock has been rallying since the release of favorable Phase 3 trial data, which has rekindled investor interest in the company's long-term growth potential in the oncology space.

What Happened

The rally began with the announcement of a successful Phase 3 trial for Moderna and Merck’s personalized mRNA cancer vaccine, intismeran, which showed promising results in melanoma patients. The trial, involving 1,137 participants, validated the therapy as a potential extension of Merck’s Keytruda. This milestone has led to a series of upward price moves, with the stock climbing over 11% in multiple sessions. On the same day, Wolfe Research upgraded Moderna to Peer Perform, citing the trial win as a catalyst for renewed momentum. Merck’s shares also surged 12.6% on the same news, reinforcing the significance of the partnership. The stock opened with a 1.5% gap up and continued to climb throughout the day, reaching a session high of $161.37 before closing near that level.

What The Data Shows

The stock has moved 147.1% over the past eight sessions, climbing from $63.33 to $156.50. Intraday volume was 35.0 million shares, or 3.1 times the 3-month average, indicating strong participation. Options activity has been heavily skewed toward calls, with $96.5 million in call premiums compared to $22.1 million in puts. The session also marked 25 fresh 52-week highs for the stock, while it traded within its 52-week range of $22.28 to $176.66. Despite the rally, Moderna remains unprofitable, with a TTM net margin of -141.4% and a TTM revenue decline of 27.6%. Insiders have sold $35.2 million in shares over the past 90 days, with the most recent filing on August 7.

What To Watch

Investors should monitor the breadth of coverage as the stock continues to attract attention. With 25 stories from 13 sources in the last 36 hours, the momentum suggests ongoing interest in the company’s oncology pipeline. No earnings date is provided, but continued trial progress or regulatory updates could shape the near-term trajectory.